Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic trip...
Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer
About this item
Full title
Author / Creator
Garrido-Castro, Ana C. , Saura, Cristina , Barroso-Sousa, Romualdo , Guo, Hao , Ciruelos, Eva , Bermejo, Begoña , Gavilá, Joaquin , Serra, Violeta , Prat, Aleix , Paré, Laia , Céliz, Pamela , Villagrasa, Patricia , Li, Yisheng , Savoie, Jennifer , Xu, Zhan , Arteaga, Carlos L. , Krop, Ian E. , Solit, David B. , Mills, Gordon B. , Cantley, Lewis C. , Winer, Eric P. , Lin, Nancy U. and Rodon, Jordi
Publisher
England: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
Treatment options for triple-negative breast cancer remain limited. Activation of the PI3K pathway via loss of PTEN and/or INPP4B is common. Buparlisib is an orally bioavailable, pan-class I PI3K inhibitor. We evaluated the safety and efficacy of buparlisib in patients with metastatic triple-negative breast cancer.
This was a single-arm phase 2...
Alternative Titles
Full title
Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer
Authors, Artists and Contributors
Author / Creator
Saura, Cristina
Barroso-Sousa, Romualdo
Guo, Hao
Ciruelos, Eva
Bermejo, Begoña
Gavilá, Joaquin
Serra, Violeta
Prat, Aleix
Paré, Laia
Céliz, Pamela
Villagrasa, Patricia
Li, Yisheng
Savoie, Jennifer
Xu, Zhan
Arteaga, Carlos L.
Krop, Ian E.
Solit, David B.
Mills, Gordon B.
Cantley, Lewis C.
Winer, Eric P.
Lin, Nancy U.
Rodon, Jordi
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_b135fa020eea478cb995d917e54e49ab
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_b135fa020eea478cb995d917e54e49ab
Other Identifiers
ISSN
1465-542X,1465-5411
E-ISSN
1465-542X
DOI
10.1186/s13058-020-01354-y
